Thousand Oaks, California (ots/PRNewswire) – Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic [...]
Tag Archive > Colorectal Cancer
EANS-Adhoc: Ad hoc Announcement According to §15 WpHG (German Securities Trading Act): Epigenomics AG signs Collaboration Agreement in Colorectal Cancer Blood Testing with QIAGEN N.V.
——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/Molecular diagnostics 28.02.2011 Berlin, Germany, February 28, 2011 – Epigenomics AG (ISIN: DE000A0BVT96) today signed an option agreement in colorectal cancer [...]
EANS-News: Epigenomics and QIAGEN Sign Collaboration Agreement in Colorectal Cancer Blood Testing
QIAGEN acquires options to mSEPT9 biomarker and DNA methylation technologies; QIAGEN granted license to pursue Septin9 product related R&D ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Joint Ventures/Cooperation/Collaboration/New Products/Molecular diagnostics Subtitle: QIAGEN acquires options to mSEPT9 biomarker and DNA methylation technologies; QIAGEN granted [...]
Kanadisches Mitglied von "Bowel Cancer International" steigert Krebsbewusstsein durch seinen "International Public Service Announcement Contest"
Toronto (ots/PRNewswire) – Die “Colorectal Cancer Association of Canada” (CCAC, kanadische Vereinigung für Kolorektalkrebs) lädt aufstrebende Werbedesigner und Filmemacher ein, ihre Talente einzusetzen, um durch ihre Teilnahme an dem zweiten Jahreswettbewerb “International Public Service Announcement (PSA) Contest” (Ausschreibungswettbewerb für öffentliche Institutionen) weltweit das Bewusstsein für Kolorektalkrebs zu fördern. Neben Bargeldpreisen von bis zu $4.500,- CAD [...]
EANS-News: Epigenomics Provides Update on Progress with US Product Development for Epi proColon
– Strong feasibility study data for improved product concept with 91% sensitivity and 87% specificity – FDA sets February date for Pre-IDE meeting ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– New Products/Molecular diagnostics Subtitle: – Strong feasibility study data for improved product concept [...]
Agendia Publishes Compelling First Independent Validation Study of Colon Cancer Recurrence Test "ColoPrint" in Journal of Clinical Oncology
Irvine, California and Amsterdam (ots/PRNewswire) – Agendia, a world leader in molecular cancer diagnostics, announced today that together with principal investigators from Spain, the UK, and the Netherlands, it has published the first independent validation study of its colon cancer recurrence test “ColoPrint” in the Journal of Clinical Oncology. The authors conclude that ColoPrint significantly [...]
EANS-News: Epigenomics AG Announces Hand-Over of CFO Responsibility by End of Q1 2011
Current CFO Oliver Schacht leaving by March 31, 2011; Experienced CFO Successor to join April 1st, 2011 ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Personnel/Molecular diagnostics Subtitle: Current CFO Oliver Schacht leaving by March 31, 2011; Experienced CFO Successor to join April 1st, [...]
EANS-News: Epigenomics Initiates Clinical Market Observation Study for Colorectal Cancer Blood Test
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Berlin and Seattle, November 23, 2010 (euro adhoc) – Epigenomics AG, the cancer diagnostics company, today announced that they have initiated an observational clinical study for the Epi proColon test to examine adoption [...]
EANS-News: Epigenomics Signs Distribution Deal with DPC for Epi proColon in Middle East
Third distribution agreement for Epi proColon completes the picture for the Middle East ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Subtitle: Third distribution agreement for Epi proColon completes the picture for the Middle East BERLIN and SEATTLE, November 5, 2010 [...]
EANS-News: Epigenomics Signs Distribution Deal with DATEKS for Epi proColon in Turkey
Second distributor to be signed-up for Epi proColon – more expected to come shortly ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Subtitle: Second distributor to be signed-up for Epi proColon – more expected to come shortly BERLIN and SEATTLE, October [...]
EANS-News: Epigenomics AG to Update on Clinical Studies with Septin9 Blood Test for Colorectal Cancer at Two Conferences in Europe and the US
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics BERLIN and SEATTLE – October 22, 2010 (euro adhoc) – Epigenomics AG, the cancer diagnostics company, today announced that it will present data from two clinical studies with its proprietary biomarker for the [...]
EANS-News: Epigenomics’ Licensee ARUP Reports Excellent Validation Results for Septin9 Colorectal Cancer Blood Test
Presentation at ASCO – NCI – EORTC Molecular Markers Meeting ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Subtitle: Presentation at ASCO – NCI – EORTC Molecular Markers Meeting Berlin and Seattle – October 20, 2010 (euro adhoc) – Epigenomics AG’s [...]
EANS-News: Epigenomics Signs Distribution Deal with Pronto Diagnostics for Epi proColon in Israel
Epigenomics expands commercial reach for CE-marked product beyond home market ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Subtitle: Epigenomics expands commercial reach for CE-marked product beyond home market Berlin, Germany, and Tel Aviv, Israel, October 14, 2010 (euro adhoc) – [...]
EANS-News: Epigenomics AG and NextPharma Sign Global Manufacturing Deal for Colorectal Cancer Blood Test
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Berlin, Germany and Surrey, United Kingdom, 6th October, 2010 (euro adhoc) – The cancer molecular diagnostics company Epigenomics AG and NextPharma Technologies, the leading European provider of product development, contract manufacturing and cold [...]
Die Colorectal Cancer Association Kanadas eröffnet den zweiten jährlichen Ausschreibungswettbewerb für Öffentliche Institutionen
Montreal (ots/PRNewswire) – Um die Mitteilung auf Social Media Release abzurufen, klicken Sie bitte auf: http://smr.newswire.ca/en/ccac/colorectal-cancer-association-launches -contest Der Darmkrebs-Verband Kanadas (CCAC – Colorectal Cancer Association of Canada) ist freut sich die Eröffnung des zweiten Ausschreibungswettbewerb des öffentlichen Dienstes am 1. September 2010 bekannt geben zu dürfen. ZIEL DES WETTBEWERBS: Der Wettbewerb dient der öffentlichen Bewusstseinssteigerung [...]
